Market Herald logo


Be the first with the news that moves the market
  • On June 7 this year, medicinal hemp manufacturer Creso Pharma popped champagne in talks of an AU$122 million buyout from Toronto based PharmaCielo
  • The deal instead faced a very rocky path, ending in Creso Pharma remaining in a voluntary suspension today
  • Third party analysis from BDO Corporate found the proposed buyout of Creso Pharma at AU$0.63 per share was unfair to shareholders — changing its initial findings a day before court hearings
  • Now BDO has backtracked its claims, giving Creso a green light with a new WA Supreme Court hearing slated for October 2 and an updated scheme booklet

Medicinal hemp manufacturer Creso Pharma has been the subject of a tumultuous buyout keeping shareholders frustrated — what’s the situation now?

For months, the Australian company has been trying to secure a million-dollar buyout from Canadian based PharmaCielo.

The Toronto-based company holds a significantly higher market cap at $510 million and has a steady business with CBD oils.

The news, which first broke on June 7, was slated to see Creso bought out by PharmaCielo for AU$122 million.

Over three months later and the deal is still up in the air, leaving shareholders with heads scratching.

The deal was to have Creso bought out for AU$0.63 per share, a premium to the share price then of AU$0.55 apiece — even higher than today’s AU$0.38 per share.

In the transaction of the deal, Creso Pharma shareholders would receive 0.0775 PharmaCielo shares per held share. On July 3, Creso Pharma began paying off outstanding debts to prepare for acquisition.

The acquisition is still yet to happen and Creso Pharma has now been in a voluntary trading suspension since September 18.

Today Creso Pharma management broke news to shareholders, in hopes to quell frustrations and provide an update.

In clearing the air, Creso Pharma management stated independent expert BDO Corporate found the proposed buyout was reasonable, although possibly unfair.

Regardless, the company maintained the deal was in the best interest of shareholders.

“We are very pleased to have received the additional certainty provided by the positive opinion of the independent expert,” Creso CEO Dr Miri Haperin Wernli said today.

On September 17, Creso was slated to appear in WA Supreme Court for consideration of the draft scheme booklet using BDO’s analysis. One day beforehand, BDO withdrew its findings.

BDO stated PharmCielo’s shares in the Toronto Exchange had declined significantly, below the previously assessed range in its analysis.

Because of this, BDO no longer considered the scheme to be in the best interest of Creso shareholders. Since the withdrawal, Creso Pharma immediately jumped into a voluntary suspension — still active today.

Since then, PharmaCielo’s shares on the Toronto Exchange have climbed once again. Now BDO Corporate has gone back on its analysis, saying the buyout is now in the best interest of Creso Pharma holders.

“The Creso Pharma board remains committed to the schemes and Creso Pharma is excited to be progressing the schemes towards completion which is now likely to occur in mid to late November 2019,” Dr Miri Herpin added.

A newly updated scheme booklet has been sent to the Australian Securities and Investments Commission and awaits review. Creso Pharma now has a new court hearing dated for October 2.

Creso Pharma intends to update shareholders after initial court hearings on the new scheme.

Share prices in Creso Pharma are unmoved today, sitting at 38.3 cents apiece in a $57.88 million market cap.

CPH by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.